Table 2 Best overall response and blast response (efficacy analysis set)

From: Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

Response characteristic

Regimen 1

Regimen 2

Regimen 3

 

60mg BID

Overall

60mg BID

Overall

60mg BID

Overall

AML (N)

3

26

3

29

9

11

 Best overall response, n (%)a

SD

3 (100.0)

12 (46.2)

2 (66.7)

17 (58.6)

4 (44.4)

5 (45.5)

PD

0 (0.0)

8 (30.8)

1 (33.3)

5 (17.2)

2 (22.2)

2 (18.2)

Not evaluable

0

6

0

7

3

4

 Blast response, n (%)

Yes

0 (0.0)

2 (7.7)

0 (0.0)

4 (13.8)

1 (11.1)

1 (9.1)

No

3 (100.0)

24 (92.3)

3 (100.0)

25 (86.2)

8 (88.9)

10 (90.0)

ALL (N)

0

1

0

0

1

1

 Best overall response, n (%)b

CRi

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (100.0)

1 (100.0)

SD

0 (0.0)

1 (100.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Blast response, n (%)

Yes

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (100.0)

1 (100.0)

No

0 (0.0)

1 (100.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

MDS (N)

0

3

0

0

2

3

 Best overall response, n (%)c

PR

0 (0.0)

1 (50.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

PD

0 (0.0)

1 (50.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Not evaluable

0

1

0

0

2

3

 Blast response, n (%)

Yes

0 (0.0)

2 (66.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

No

0 (0.0)

1 (33.3)

0 (0.0)

0 (0.0)

2 (100.0)

3 (100.0)

MPD (N)

0

1

1

2

0

0

 Best overall response, n (%)d

SD

0 (0.0)

1 (100.0)

1 (100.0)

1 (100.0)

0 (0.0)

0 (0.0)

Not evaluable

0

0

0

1

0

0

 Blast response, n (%)

Yes

0 (0.0)

1 (100.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

No

0 (0.0)

0 (0.0)

1 (100.0)

2 (100.0)

0 (0.0)

0 (0.0)

MM (N)

1

2

0

1

0

0

 Best overall response, n (%)e

SD

1 (100.0)

1 (50.0)

0 (0.0)

1 (100.0)

0 (0.0)

0 (0.0)

PD

0 (0.0)

1 (50.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Blast response, n (%)

Yes

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

No

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Not evaluable

1

2

0

1

0

0

  1. Abbreviations: ALL, acute lymphotic leukemia; AML, acute myelocytic leukemia; BID, twice daily; CI, clinical improvement; CR, complete remission (morphological for AML); CRi, morphological complete remission with incomplete blood count recovery; CY, cytogenetic response; HI, hematologic improvement major; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPD, myeloproliferative disorders; NCR, near complete response; NO, no response; PD, progressive disease; PR, partial response; PS, plateau state; SD, stable disease.
  2. aAML: no patient achieved CR, CRi, PR, or CY.
  3. bALL: No CR, PR, PD, or CY responses observed. All patients evaluable.
  4. cMDS: No CR, HI, or CY responses observed.
  5. dMPD: No CR, CI, PR, or PD responses observed.
  6. eMM: No CR, NCR, PR, NO, or PS responses observed. All patients evaluable.
Back to article page